Key result
Polypharmacy, seen in about 40% of people over 75 years of age worldwide, increases the risk of drug side effects, drug-drug interactions, and unwanted hospitalizations.
This review emphasizes the high prevalence of polypharmacy in the elderly and the importance of minimizing drug regimens to prevent adverse events, particularly with cardiovascular medications.
Supports medication review in elderly CV patients; leaves optimal deprescribing strategies open.
Although the definition of polypharmacy is not yet clear today, it is generally regarded as drug use more than the patient needs. Advanced age is the most important risk factor for polypharmacy. In addition, other risk factors are loss of current cognitive functions, low socioeconomic level and nursing care. It is seen in about 40% of people over 75 years of age worldwide, varying between countries of extreme poverty. Incorrect drug use, drug side effects and drug-drug interaction lead to unwanted hospitalizations. In particular, cardiovascular drugs pose risks in terms of drug side effects in advanced ages. Altering the pharmacokinetics and pharmacodynamics of the drug along with advanced age lead to more frequent side effects or no effect of the drugs. The most important point to prevent polypharmacy is to inform the patient or the patient's caregiver fully and to target treatment with a minimum number of drugs and doses.
No takes yet. Share an insight, caveat, or question.
Aytül Belgi Yıldırım (2017) conducted a review in Polypharmacy. Polypharmacy was evaluated. Polypharmacy, seen in about 40% of people over 75 years of age worldwide, increases the risk of drug side effects, drug-drug interactions, and unwanted hospitalizations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology